Premier Alternatives

Vergent Bioscience

Minneapolis, MN · Founded 2013 · Privately Held (backing)

Developer of molecular imaging probes designed for the diagnosis and removal of cancer cells. Vergent Bioscience is based in Minneapolis, MN and was founded in 2013. It was valued at $75 million at its later-stage round in Oct 2025, the last priced event on record. It has raised $56.4 million across 5 recorded rounds; the latest was an $18.7 million early-stage round in Oct 2025.

PMV mark · valuation
$75.0M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$56.4M
Last round
Early Stage VC
Oct 2025

Vergent Bioscience key facts

as of Oct 2026
  • Developer of molecular imaging probes designed for the diagnosis and removal of cancer cells.
  • Vergent Bioscience is valued at approximately $75.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $56.4M across 5 recorded rounds; the latest was Early Stage VC ($18.7M) in Oct 2025.
  • Notable investors include National Institutes of Health, Spring Mountain Capital, Colle Capital Partners, Intuitive Surgical, Orlando Health Ventures — 7 tracked in total.
  • Vergent Bioscience has filed 7 Form Ds with the SEC since 2018, most recently Feb 2025 ($3.8M sold to 5 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$75.0M

Valued at $75.0M at its later-stage round, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Vergent Bioscience with a free account
  • ·Watch Vergent Bioscience: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Vergent Bioscience funding rounds

5 rounds
Oct 2025Early Stage VC$18.7MSEC filing▮
Feb 2025Seed Round$3.8MSEC filing▮
Aug 2022Early Stage VC$21.5MSEC filing▮
Nov 2021Seed Round$1.2MSEC filing▮
May 2018Early Stage VC$11.9MSEC filing▮
Full funding history →

Vergent Bioscience valuation

Vergent Bioscience was valued at $75 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Vergent Bioscience raised?

Vergent Bioscience has raised $56.4 million across 5 recorded rounds since 2018. The largest was a $3.8 million seed round in Feb 2025; the most recent was an $18.7 million early-stage round in Oct 2025.

Vergent Bioscience has filed 7 Form Ds with the SEC since 2018, most recently in Feb 2025 ($3.8 million sold to 5 investors).

Vergent Bioscience investors

7 investors are on record for Vergent Bioscience, including National Institutes of Health, Spring Mountain Capital, Colle Capital Partners and Intuitive Surgical. The early-stage round in Oct 2025 drew 20 investors.

About Vergent Bioscience

Developer of molecular imaging probes designed for the diagnosis and removal of cancer cells. The company develops molecularly-targeted probes that bind to enzymes that are over-expressed in tumor tissue, activating a brightly fluorescing dye when injected before surgery, enabling surgeons to locate and completely remove tumors during resection surgery through improved visual clarity.

Sector
Healthcare
HQ
Minneapolis, MN, United States
Founded
2013
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.